Compare Air Products & Chemicals, Inc. (APD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Air Products & Chemicals, Inc. vs Smith & Nephew plc — how do they compare? Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.88B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Air Products & Chemicals, Inc. is far larger — about 5.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| APD | SNN | |
|---|---|---|
Market Cap | $68.88B | $12.54B |
Sector | Basic Materials | Health |
52-Week High | $314.19 | $38.70 |
52-Week Low | $230.42 | $28.73 |
Enterprise Value | $86.06B | $15.57B |
Dividend Yield | 2.34% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Air Products and Chemicals (APD) trades at $304.01, down 1.35% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though recent profitability metrics show negative net income margin and ROE. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance, while analyst consensus remains strongly positive with a $346 price target representing 14% upside potential.
The outlook remains constructive given earnings momentum and strategic contract wins, but investors face risks from elevated valuation multiples and recent negative profitability. The stock's technical strength and institutional support provide near-term catalysts, though margin recovery and debt management will be critical for sustained upside.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
